               SEQUENCE LISTING

<110> Forschungszentrum Juelich GmbH

<120> VERWENDUNG VON D-ENANTIOMEREN PEPTIDIDLIGANDEN VON MONOMEREM TAU FÜR DIE THERAPIE VERSCHIEDENER TAUOPATHIEN

<130> D/FZJDUE-042-DE

<160> 7

<170> BiSSAP 1.3.6

<210> 1
<211> 17
<212> PRT
<213> Artificial Sequence


<220> 
<223> D-Peptide

<400> 1
Asn Glu Met Tyr Leu Trp His Trp Gln Tyr Pro Gln His Leu Arg Val 
1               5                   10                  15      
Gly 
    

<210> 2
<211> 16
<212> PRT
<213> Artificial Sequence


<220> 
<223> D-Peptide

<400> 2
Asp Gly Gly Tyr Gln Ile Leu Phe Lys Ile Pro Gly Gly His Ile His 
1               5                   10                  15      



<210> 3
<211> 21
<212> PRT
<213> Artificial Sequence


<220> 
<223> D-Peptide

<400> 3
Asn Glu Met Tyr Leu Trp His Trp Gln Tyr Pro Gln His Leu Arg Val 
1               5                   10                  15      
Arg Arg Arg Arg Arg 
            20      

<210> 4
<211> 21
<212> PRT
<213> Artificial Sequence


<220> 
<223> D-Peptide

<400> 4
Asn Glu Leu Tyr Leu Trp His Trp Gln Tyr Pro Gln His Leu Arg Val 
1               5                   10                  15      
Arg Arg Arg Arg Arg 
            20      

<210> 5
<211> 21
<212> PRT
<213> Artificial Sequence


<220> 
<223> D-Peptide

<400> 5
Asp Gly Gly Tyr Gln Ile Leu Phe Lys Ile Pro Gly Gly His Ile His 
1               5                   10                  15      
Arg Arg Arg Arg Arg 
            20      

<210> 6
<211> 21
<212> PRT
<213> Artificial Sequence


<220> 
<223> D-Peptide

<400> 6
Arg Ser Ser Tyr Gln Ile Leu Phe Arg Ile Pro Ser Ser His Ile His 
1               5                   10                  15      
Arg Arg Arg Arg Arg 
            20      

<210> 7
<211> 18
<212> PRT
<213> Artificial Sequence


<220> 
<223> D-Peptide

<400> 7
Tyr Gln Ile Leu Phe Arg Ile Pro Ser Ser His Ile His Arg Arg Arg 
1               5                   10                  15      
Arg Arg 
        

